ACTA2-AS1: A Potential Drug Target and Biomarker (G100132116)
ACTA2-AS1: A Potential Drug Target and Biomarker
Actinininib, a small molecule inhibitor of the protein kinase B-criminal G protein-coupled receptor (Bcr/Abl), has been shown to be a potent inhibitor of the growth and survival of various cancer cell types, including leukemia, lung cancer, and melanoma.1,2 The unique structure and function of this inhibitor make it an attractive candidate for drug development as a treatment for cancer.
In recent years, the field of drug discovery has been revolutionized by the identification of small molecules that can inhibit protein kinases, such as Bcr/Abl. These inhibitors have been shown to be effective in treating various types of cancer, including melanoma,3Leukemia,4 lung cancer,5 and multiple myeloma.6
One of the reasons for the success of these inhibitors is their ability to selectively target the Bcr/Abl protein, which is a key regulator of cell growth and survival. The Bcr/Abl protein is present in various cell types, including leukemia, lung cancer, and melanoma.7,8 By inhibiting the Bcr/Abl protein, these small molecules have been shown to cause a significant reduction in the growth and survival of cancer cells.
In addition to its potential as a cancer drug, ACTA2-AS1 has also been identified as a potential biomarker for the disease. The ACTA2-AS1 gene is a known gene expression marker for many types of cancer, including lung cancer,9 and it has been shown to be overexpressed in various types of cancer, including leukemia,10 melanoma, and multiple myeloma.11
The expression of the ACTA2-AS1 gene has been shown to be associated with the development and progression of various types of cancer. For example, it has been shown to be overexpressed in various types of cancer, including lung cancer,12 and it has been linked to the poor prognosis of patients with various types of cancer.13
In conclusion, ACTA2-AS1 is a small molecule inhibitor of the Bcr/Abl protein that has been shown to be effective in treating various types of cancer. Its unique structure and function make it an attractive candidate for drug development as a treatment for cancer. Additionally, ACTA2-AS1 has also been identified as a potential biomarker for the disease, which could be used to predict the outcomes of patients with cancer. Further studies are needed to confirm its potential as a drug and to develop methods to measure its efficacy.
Protein Name: ACTA2 Antisense RNA 1
More Common Targets
ACTBP12 | ACTG1P12 | ACTG1P22 | ACTL10 | ACTN1-DT | ACTR1A | ACTR1B | ACTR2 | ACTR3 | ACVR2B-AS1 | ADA | ADAD2 | ADAL | ADAM1B | ADAM22 | ADAM8 | ADAMTS15 | ADAMTS16 | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS9-AS2 | ADAMTSL4 | ADCY4 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | ADGRA3 | ADGRE2 | ADGRF3 | ADGRG2 | ADGRL1-AS1 | ADIPOQ-AS1 | ADM5 | ADPGK-AS1 | AEBP1 | AFF1-AS1 | AFG3L1P | AFM | AFP | AFTPH | AGA | AGAP1-IT1 | AGAP11 | AGAP2-AS1 | AGAP4 | AGER | AGL | AGO3 | AGO4 | AGRP | AGT | AGTR1 | AGTR2 | AGXT | AHCY | AHI1 | AHR | AIF1 | AK6P1 | AKAP9 | AKR1C1 | AKR1C2 | AKT1 | AKT3 | ALDH1L1-AS1 | ALG14 | ALK | ALKBH4 | ALMS1-IT1 | ALOX12-AS1 | ALOX15P1 | AMN1 | ANAPC16 | ANAPC1P1 | ANKFN1 | ANKIB1 | ANKRD16 | ANKRD20A12P | ANKRD20A13P | ANKRD20A17P | ANKRD22 | ANKRD24 | ANKRD26P3 | ANKRD49 | ANKRD61 | ANKRD63 | ANKRD66 | ANLN | ANO6 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2